HER2-negative — trastuzumab not indicated
Gene: ERBB2 · Type: expression
Indications: Breast cancer
Linked CIViC Profile: ERBB2 EXPRESSION
Evidence Level Distribution
Level A: 23Level B: 54Level C: 25Level D: 42
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Predictive | Supports | Resistance | Breast Cancer | Lapatinib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib,Lapatinib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib | 5 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab | 5 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab | 5 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Docetaxel,Trastuzumab,Pertuzumab | 5 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Trastuzumab Deruxtecan | 5 |
| A | Predictive | Supports | Sensitivity/Response | Breast Cancer | Margetuximab | 5 |
| A | Predictive | Supports | Sensitivity/Response | Solid Tumor | Trastuzumab Deruxtecan | 5 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib,Lapatinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Neratinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Breast Cancer | Lapatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Lapatinib,Trastuzumab | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Lapatinib,Trastuzumab | 4 |